Abeona Therapeutics (ABEO) vs Larimar Therapeutics (LRMR)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Abeona Therapeutics (ABEO) has outperformed Larimar Therapeutics (LRMR) over the past year, losing 3.2% versus a loss of 41.7%. Over five years, LRMR leads with a -77.3% price change compared with -77.7% for ABEO. Abeona Therapeutics is the larger company by market cap ($285.1 million vs $280.0 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ABEO | LRMR |
|---|---|---|
| Share price | $4.99 | $2.70 |
| Market cap | $285.06M | $279.96M |
| 1-day change | -1.87% | -2.00% |
| YTD return | -3.61% | -27.82% |
| 1-year return | -3.24% | -41.74% |
| 5-year return | -77.67% | -77.31% |
| EPS (TTM) | $-1.18 | $-1.99 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $7.65 | $6.42 |
| 52-week low | $4.00 | $2.61 |
| Distance from 52-week high | -34.84% | -58.02% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +278.74% | +434.32% |
| Average volume | 1.41M | 1.31M |
| Shares outstanding | 57.18M | 103.88M |
| Employees | 226 | 71 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- ABEO has outperformed LRMR by 38.5 percentage points over the past year.
About Abeona Therapeutics
ABEO stock →Abeona Therapeutics Inc., a commercial-stage biopharmaceutical company, develops gene and cell therapies for life-threatening diseases in the United States. It develops ZEVASKYN, an autologous, cell-based gene therapy for the treatment of patients with recessive dystrophic epidermolysis bullosa.
Health Care · Biotechnology: Pharmaceutical Preparations · 226 employees
About Larimar Therapeutics
LRMR stock →Larimar Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601, which is in Phase 2 OLE clinical trial for the treatment of Friedreich's ataxia, a rare, progressive and fatal disease.
Health Care · Biotechnology: Pharmaceutical Preparations · 71 employees
ABEO vs LRMR FAQ
Which is bigger, Abeona Therapeutics or Larimar Therapeutics?
Abeona Therapeutics (ABEO) is larger, with a market capitalization of $285.06M compared with $279.96M for Larimar Therapeutics (LRMR).
Which stock has performed better over the past year, ABEO or LRMR?
ABEO returned -3.24% over the past 12 months, compared with -41.74% for LRMR (price return, excluding dividends). Past performance does not predict future results.
Are Abeona Therapeutics and Larimar Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.